Review  Open Access
| |
|
| Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association |
Hyun Jin Kim,1 Seok O Park , 2 Seung-Hyun Ko,3 Sang Youl Rhee,4 Kyu-Yeon Hur,5 Nan-Hee Kim,6 Min Kyong Moon,7 Byung-Wan Lee,8 Jin Hwa Kim,9 Kyung Mook Choi,6 and on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association |
| 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. |
| 2Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. |
| 3Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. |
| 4Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. |
| 5Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. |
| 6Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. |
| 7Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. |
| 8Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. |
| 9Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea. |
Corresponding author: Seok O Park. Department of Internal Medicine, Gwangmyeong Sungae Hospital, 36 Digital-ro, Gwangmyeong 14241, Korea. Email: dmbak@sungae.co.kr
|
| |
Received October 19, 2017; Accepted November 28, 2017.
|
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
|
|
|
Abstract
|
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017 for pharmacological therapy. Many randomized clinical trials and systematic reviews report that GLP-1RAs have considerable glucose-lowering effect and lead to weight reduction and low risk of hypoglycemia when used as a monotherapy or combination therapy. The cardiovascular safety of GLP-1RAs has been assessed in several randomized clinical trials and systematic reviews. The results of cardiovascular outcome trials of long-acting GLP-1RAs (liraglutide, semaglutide) demonstrated cardiovascular benefits in subjects with type 2 diabetes mellitus and a high risk of cardiovascular disease. The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
|
| |
|
Keywords:
Cardiovascular benefit; Clinical practice guideline; Combination therapy; Glucagon-like peptide-1 receptor agonist; Hypoglycemia; Monotherapy
|
|
[1]
